Monkeypox future or investigational therapies
|
Monkeypox Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Monkeypox future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Monkeypox future or investigational therapies |
|
Risk calculators and risk factors for Monkeypox future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Bassel Almarie, MD
Overview
Countries are developing policies to define high risk groups to receive vaccines. Clinical investigations will be running to evaluate the appropriateness of vaccination to contain the outbreak[1].
Future or investigational therapies
Countries are developing policies to define high risk groups to receive vaccines. Clinical investigations will be running to evaluate the appropriateness of vaccination to contain the outbreak[1].
- Antibiral agents such as Cidofovir or Tecovirimat were evaluated only for safety but not efficacy on human models. Future trials may evaluate the drug’s effectiveness to treat humans cases of monkeypox[2][3][4].
References
- ↑ 1.0 1.1 "Monkeypox". Retrieved 2022-06-16.
- ↑ De Clercq E (2002). "Cidofovir in the treatment of poxvirus infections". Antiviral Res. 55 (1): 1–13. doi:10.1016/s0166-3542(02)00008-6. PMID 12076747.
- ↑ Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, Strasser J; et al. (2008). "Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor". Antimicrob Agents Chemother. 52 (5): 1721–7. doi:10.1128/AAC.01303-07. PMC 2346641. PMID 18316519.
- ↑ Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF; et al. (2012). "Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers". Antimicrob Agents Chemother. 56 (9): 4900–5. doi:10.1128/AAC.00904-12. PMC 3421894. PMID 22777041.